Gore received approval to apply the CE Mark and commence commercial distribution of its GORE VIABAHN^® Endoprosthesis with PROPATEN Bioactive Surface in the European Union. Additionally, Gore recently received approval by the Therapeutic Goods Administration to commence commercial distribution in Australia. The GORE VIABAHN^® Endoprosthesis with PROPATEN Bioactive Surface combines Gore's proprietary heparin surface with the proven performance of the GORE VIABAHN^® Endoprosthesis for treatment of arterial vascular disease. GORE VIABAHN^® Endoprosthesis with PROPATEN Bioactive Surface is indicated for the endovascular grafting of peripheral arteries. GORE VIABAHN^® Endoprosthesis with PROPATEN Bioactive Surface (5 to 8 mm devices) is available with a low-profile delivery system that gives interventionalists a more streamlined approach to re-line the peripheral arteries.